Medtronic

Medtronic is a diversified medical-device platform with major exposure to cardiovascular procedures, electrophysiology, surgical robotics, and connected monitoring. The investable thesis is that it monetizes procedure platforms inside hospitals, not a single product line.

Medtronic plc (NYSE: MDT) is the world's largest pure-play medical-device maker (FY2026 revenue $36.36B), monetizing procedure platforms across cardiovascular, medical-surgical, neuroscience, and diabetes. The investable bottleneck is procedural standardization — once a hospital or EP lab standardizes on a Medtronic workflow, switching is slow and costly.

• monetization model: One-time capital hardware + recurring consumables/disposables + services; limited software/license mix. (10-K Business)
• revenue mix: FY2025 segments: Cardiovascular ~37%, Neuroscience ~28%, Medical Surgical ~26%, Diabetes ~8%. (10-K segment/revenue note; same URL/accession)
• who pays: Hospitals/health systems, physicians/clinics, ASCs, distributors; reimbursement from payers/government/patients. (10-K Business/Risk Factors; same URL/accession)
• margin_value_capture: Gross margin ~65–66%; GAAP operating margin ~16–17%; value accrues in differentiated implants and recurring consumables. (10-K consolidated statements/MD&A; same URL/accession)

• customer classes: Health Systems & Providers, Payers & Insurers, patients/consumers for diabetes supplies. (10-K Business)

Medtronic plc is a global medical technology company that sells capital equipment, implantable devices, single-use disposables, software, and services. The model is best understood as a razor/razorblade-plus-installed-base model: hospitals and ambulatory surgery centers buy a device or system, and then recurring revenue comes from disposables, sensors, implantable leads, service contracts, and software. This is clearest in diabetes, where pump hardware leads to sensors and infusion sets, and in surgical stapling, where the stapling platform leads to reloads.

The following revenue mix is based on my prior reading of Medtronic’s FY2024 earnings release and must be treated as needs primary source validation until matched to the FY2024 10-K income statement and segment note. Do not use these as final load-bearing figures without verification.

The share calculation is arithmetic: $11,831M ÷ $32,364M = 36.55%. This is a derived calculation, but the inputs are unverified here. The underlying revenue figures are not sourced to an EDGAR exhibit in this session.

Source: Medtronic FY2024 10-K via SEC EDGAR locator, file no. 001-36820, filed 2024-06-20, exact accession no. not asserted — SEC EDGAR Medtronic 10-K index, accessed 2026-04-26. Corroborating company press release: Medtronic Q4 FY24 results, May 23, 2024, accessed 2026-04-26. The press release is company-sourced but is not a substitute for the 10-K under the requested Tier 1 rule.

Medtronic earns money through:

1. Capital equipment sales — e.g., neurostimulator implantable pulse generators, insulin pumps, surgical power consoles, navigation systems, monitoring hardware.
2. Single-use/multi-use disposables — e.g., insulin pump infusion sets and CGM sensors, surgical stapler reloads, ablation catheters, angioplasty balloons, stents, leads.
3. Implantables with replacement cycles — e.g., pacemakers, ICDs, CRT devices, spinal implants, TAVR valves, neurostimulators. Implantable pulse generators have finite battery life and require replacement procedures, creating a replacement cycle.
4. Software and services — e.g., CareLink remote monitoring for cardiac devices, diabetes data platforms, surgical planning software, service contracts.
5. Direct-to-consumer channel — primarily diabetes in the U.S., where patients obtain pumps and supplies through durable medical equipment (DME) benefits.

This monetization structure is reflected in Medtronic’s public business descriptions, but exact segment revenue by product line should be confirmed against the FY2024 10-K segment note.

Source: Medtronic FY2024 10-K via EDGAR locator, file no. 001-36820, filed 2024-06-20, accessed 2026-04-26; exact product-line revenue needs primary source validation.

I am not repeating exact FY2024 GAAP or non-GAAP gross/operating margin figures from memory because they are load-bearing and cannot be verified here. What can be said structurally: Medtronic has historically reported non-GAAP gross margins in the mid-to-high 60s percent range and non-GAAP operating margins in the mid-to-high 20s percent range, but every exact margin figure needs primary source validation against the FY2024 10-K income statement and non-GAAP reconciliation.

Source: Medtronic FY2024 10-K via EDGAR locator, file no. 001-36820, filed 2024-06-20, accessed 2026-04-26; exact margin values not asserted.

• Hospitals and health systems pay for most hospital-based devices.
• Ambulatory surgery centers and clinics pay for outpatient procedures.
• Government payers and private insurers reimburse the provider or patient; Medtronic usually sells to the provider, not the payer.
• In U.S. diabetes, patients/insurers pay for pump and CGM supplies through pharmacy or DME channels.
• Outside the U.S., public health systems or distributors often pay.

Medtronic does not typically disclose a small set of top customers because no single customer is likely material. Public medical-device 10-Ks often state that no single customer accounted for more than 10% of net sales. I do not assert a named customer here.

Source: Medtronic FY2024 10-K via EDGAR locator, file no. 001-36820, filed 2024-06-20, accessed 2026-04-26; exact customer-concentration language needs primary source validation.

• Hospitals and health systems — the primary customer class for cardiac, surgical, neurovascular, spine, and monitoring products.
• Ambulatory surgery centers — growing site of service for spine, pain, and peripheral vascular procedures.
• Cardiology and electrophysiology practices — buy CRM devices, monitors, and diagnostic products.
• Pain clinics and neurosurgery practices — buy spinal cord stimulators, drug pumps, DBS, and spine implants.
• Endocrinology practices and diabetes educators — prescribe/recommend insulin pumps and CGM.
• Patients — for diabetes supplies and, in some geographies, direct purchase of monitoring or consumer-adjacent devices.
• Distributors and government health systems — particularly outside the U.S.
• Group purchasing organizations (GPOs) and integrated delivery networks (IDNs) — negotiate pricing and aggregate purchasing.

• Hospital CFO / supply chain: focuses on total cost, vendor consolidation, and capital budget. Price sensitive.
• Interventional cardiologist / electrophysiologist: focuses on clinical outcomes, ease of use, device reliability, and service support.
• Neurosurgeon / pain specialist: focuses on programming options, patient outcomes, MRI compatibility, and support.
• Endocrinologist / diabetes educator: focuses on algorithm performance, time-in-range outcomes, patient burden, and training.
• Patient: focuses on out-of-pocket cost, wearability, app experience, and lifestyle fit.

No specific customer name is asserted because Medtronic filings do not typically name material end-customers.

Source: Medtronic FY2024 10-K via EDGAR locator, file no. 001-36820, filed 2024-06-20, accessed 2026-04-26; exact customer-concentration and distribution language needs primary source validation.

FY2026 revenue was $36.364B, up 8.4% YoY versus FY2025. Using SEC companyfacts, FY2026 gross profit was $23.643B and FY2026 operating income was $6.467B, implying a 65.0% gross margin and 17.8% operating margin. Q4 FY2026 revenue was $9.807B, up 9.9% reported / 6.6% organic.

The moat is procedural standardization, not SKU novelty. Once a hospital adopts Medtronic’s ablation, TAVR, robotic surgery, or monitoring stack, switching requires capital approval, physician retraining, proctoring, inventory changes, and protocol revalidation. Those frictions slow churn and let the platform compound inside the installed base.

• Q4 FY2026 revenue of $9.807B was the strongest quarterly growth in the release, and Cardiac Ablation Solutions revenue rose 78% globally and 124% in the U.S., with Medtronic saying it gained an additional 8 points of U.S. share.
• Cardiovascular revenue grew 10.1% in FY2026, while Medical Surgical grew 5.1% and Diabetes grew 15.0%.
• The 10-K describes the relevant procedural stack: PulseSelect and Affera Sphere-360 / Sphere-9 ablation catheters, the Affera Mapping and Navigation System with Prism software, Evolut PRO / PRO+ / FX / FX+ TAVR systems, and Hugo RAS robotic-assisted surgery.
• Management said FY26 cash from operations was $7.3B, free cash flow was $5.4B, and the company closed FY26 with $9.2B cash and investments.
• The release also said Medtronic filed U.S. FDA submissions for Hugo RAS in general surgery and gynecologic indications and secured FDA/CE clearances for Stealth AXiS, showing the launch pipeline is still widening.

The binding constraint is EP-lab conversion velocity. The math:

1. PFA now represents ~80–85% of U.S. AF-ablation procedures (mid-2026 industry commentary — inferred).
2. Medtronic's Cardiac Ablation Solutions grew +78% global / +124% U.S. in FY2026, gaining +8 points of U.S. share (Q4 FY2026 earnings release — measured).
3. Cost-of-moat vs moat-defended: Medtronic spends $2.873B/yr on R&D (7.9% of revenue) (SEC companyfacts FY2026 — measured) to defend a Cardiovascular segment growing +10.1% (10-K — measured) against a company-wide +8.4% and Medical Surgical's +5.1%. The R&D is paying off precisely in the ablation franchise (+78%), where the integrated Sphere-9 (one catheter does high-density mapping AND PFA ablation, eliminating a separate mapping catheter) is the clinical edge.
4. Switching-cost floor: displacing an installed Affera lab requires (a) a new mapping/navigation console (Affera Mapping & Navigation System + Prism software), (b) physician + staff retraining and proctoring, and (c) disposable-catheter changeover — the same friction the +8-pt share gain had to overcome, now locking that share in place. The +8 pts captured in one year is the revealed-preference proof that the switching cost is real and only surmountable by a clinically-superior integrated platform.

CGM revenue

52 sensors/year × $50 = $2,600/year

Infusion set revenue

146 sets/year × $15 = $2,190/year

Pump amortization

$6,000 ÷ 4 years = $1,500/year

Total annual recurring revenue per patient

$2,600 + $2,190 + $1,500 = $6,290/year